Science magazine has chosen twice-yearly lenacapavir PrEP as its 2024 Breakthrough of the Year, recognizing it as a game-changer in the fight to end the global HIV epidemic. Looking ahead, once-yearly ...

Many HIV/AIDS researchers are now hopeful that the drug, lenacapavir, will powerfully drive down global infection rates when used as pre-exposure prophylaxis (PrEP), the journal said. "It has the ...

Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug ...

A Gilead representative received a standing ovation at AIDS24, held in July in Munich, Germany, after unveiling data from the PURPOSE 1 trial (NCT04994509) of lenacapavir for HIV PReP. In a Phase ...

A new drug is hugely effective at protecting people from HIV infection and needs to be injected only twice a year.

Specific objectives include: to evaluate the efficacy, safety, and acceptability of injectable lenacapavir as an additional PrEP option for populations at substantial risk of HIV infection ...

Lenacapavir has shown high efficacy in managing multidrug-resistant cases, offering hope to patients with limited alternatives. A significant breakthrough in treating the Human Immunodeficiency ...

Analysts are particularly optimistic about lenacapavir's ability to drive overall PrEP compliance. Gilead anticipates that the drug could increase PrEP adherence to 50% by 2030, up from ...

In a major step forward in the fight against HIV/AIDS, the US Food and Drug Administration (FDA) has approved Lenacapavir, an ...

A significant breakthrough in treating the Human Immunodeficiency Virus came recently with the US Federal Drug Administration approving lenacapavir, a new prototype medication. It uses a unique ...

It is the first time that a PrEP trial has been shown to prevent any HIV infections from slipping through the net, according to Gilead, and showed a subcutaneous injection with lenacapavir every ...